title: Eosinophilic pustular folliculitis effectively treated with recombinant interferon-gamma: suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells.
abstract: Eosinophilic pustular folliculitis (EPF) is characterized clinically by pruritic grouped follicular papules and pustules on the trunk, limbs, and face, and, histologically, by follicular infiltration with eosinophils. The blood eosinophil count is elevated in most patients. Oral minocycline, nonsteroidal anti-inflammatory drugs, diaminodiphenylsulphone, and corticosteroids may induce remission. We report two Japanese men with EPF who responded poorly to the usual therapy. Intravenous injections of recombinant interferon-gamma (rIFN-gamma), 5 x 10(5) to 2 x 10(6) Japan Reference Unit (JRU) (1 JRU roughly corresponds to 4 NIH units) daily for 7 days, cleared the skin lesions and returned the peripheral eosinophil counts to normal in both patients. However, the lesions recurred 2-3 days after rIFN-gamma was stopped. Both patients have received intravenous rIFN-gamma once or twice a week for nearly 1 year without systemic side-effects. Reverse transcriptase-polymerase chain reaction revealed a decreased expression of interleukin 5 (IL-5) mRNA in peripheral mononuclear cells after the rIFN-gamma therapy. rIFN-gamma may become the treatment of choice in recalcitrant EPF, although further studies are needed. It may work by interfering with the immunological function of type 2 T-helper cells, including IL-5 production responsible for the growth and differentiation of eosinophils.
authors: Department of Dermatology, Hamamatsu University School of Medicine, Japan.
authors: M
authors: M
authors: Fushimi
authors: Y
authors: Y
authors: Tokura
authors: Y
authors: Y
authors: Sachi
authors: H
authors: H
authors: Hashizume
authors: H
authors: H
authors: Sudo
authors: H
authors: H
authors: Wakita
authors: F
authors: F
authors: Furukawa
authors: M
authors: M
authors: Takigawa
mesh_terms: D000328:Adult; D001483:Base Sequence; D004802:Eosinophilia / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005499:Folliculitis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D015848:Interleukin-5 / Q000096:biosynthesis* / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008297:Male; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics; D011994:Recombinant Proteins
chemical_list: D015848:Interleukin-5; D012333:RNA, Messenger; D011994:Recombinant Proteins; D007371:Interferon-gamma